{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:30:32Z","timestamp":1791880232059,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment with CD19-directed (CAR) T cells has evolved as a standard of care for multiply relapsed or refractory large B-cell lymphoma (r\/r LBCL). A common side effect of this treatment is the immune effector cell\u2013associated neurotoxicity syndrome (ICANS). Severe ICANS can occur in up to 30% to 40% of patients treated with axicabtagene-ciloleucel (axi-cel), usually within the first 4 weeks after administration of the dose and usually responding well to steroids. We describe a case of progressive central neurotoxicity occurring 9 months after axi-cel infusion in a patient with r\/r LBCL who had undergone a prior allogeneic hematopoietic cell transplant. Despite extensive systemic and intrathecal immunosuppression, neurological deterioration was inexorable and eventually fatal within 5 months. High CAR T-cell DNA copy numbers and elevated levels of interleukin-1 (IL-1) and IL-6 were found in the cerebral spinal fluid as clinical symptoms emerged, and CAR T-cell brain infiltration was observed on autopsy, suggesting that CAR T cells played a major pathogenetic role. This case of unexpected, devastating, late neurotoxicity warrants intensified investigation of neurological off-target effects of CD19-directed CAR T cells and highlights the need for continuous monitoring for late toxicities in this vulnerable patient population.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004889","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T19:17:20Z","timestamp":1631128640000},"page":"3789-3793","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Fatal late-onset CAR T-cell\u2013mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma"],"prefix":"10.1182","volume":"5","author":[{"given":"Susanne","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Medicine, Diakonie Hospital, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1256-173X","authenticated-orcid":false,"given":"Jochen","family":"Greiner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diakonie Hospital, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"von Harsdorf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diakonie Hospital, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diakonie Hospital, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Moll","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diakonie Hospital, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6209","authenticated-orcid":false,"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University of T\u00fcbingen, T\u00fcbingen, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosmas","family":"Kandilaris","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University of T\u00fcbingen, T\u00fcbingen, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-1031","authenticated-orcid":false,"given":"Volker","family":"Daniel","sequence":"additional","affiliation":[{"name":"Transplantation Immunology, Institute of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"issue":"27","key":"2021100415292870700_B1","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"issue":"21","key":"2021100415292870700_B2","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma [published correction appears in","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"issue":"13","key":"2021100415292870700_B3","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"2021100415292870700_B4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","article-title":"Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B Cell lymphoma","volume":"26","author":"Oluwole","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2021100415292870700_B5","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"2021100415292870700_B6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol."},{"issue":"27","key":"2021100415292870700_B7","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021100415292870700_B8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.bbmt.2020.04.025","article-title":"Feasibility and safety of CD19 chimeric antigen receptor T Cell treatment for B Cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Schubert","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2021100415292870700_B9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica."},{"key":"2021100415292870700_B10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.omtm.2020.02.003","article-title":"Optimized assessment of qPCR-Based vector copy numbers as a safety parameter for GMP-Grade CAR T cells and monitoring of frequency in patients","volume":"17","author":"Kunz","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"10","key":"2021100415292870700_B11","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.3390\/cancers12102820","article-title":"Assessment of CAR T Cell frequencies in axicabtagene ciloleucel and tisagenlecleucel patients using duplex quantitative PCR","volume":"12","author":"Schubert","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"10","key":"2021100415292870700_B12","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv."},{"issue":"21","key":"2021100415292870700_B13","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/bloodadvances.2019000289","article-title":"Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia","volume":"3","author":"Alsawah","year":"2019","journal-title":"Blood Adv."},{"issue":"8","key":"2021100415292870700_B14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/IAE.0b013e3181d20589","article-title":"Rapid vision loss associated with fludarabine administration","volume":"30","author":"Bishop","year":"2010","journal-title":"Retina."},{"issue":"10","key":"2021100415292870700_B15","first-page":"1225","article-title":"Central nervous system toxicity of fludarabine phosphate","volume":"70","author":"Chun","year":"1986","journal-title":"Cancer Treat Rep."},{"issue":"1","key":"2021100415292870700_B16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.1986.4.1.74","article-title":"Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity","volume":"4","author":"Warrell","year":"1986","journal-title":"J Clin Oncol."},{"issue":"10254","key":"2021100415292870700_B17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"issue":"42","key":"2021100415292870700_B18","doi-asserted-by":"crossref","first-page":"e8303","DOI":"10.1097\/MD.0000000000008303","article-title":"Case report: central nervous system involvement of human graft versus host disease: report of 7 cases and a review of literature","volume":"96","author":"Ruggiu","year":"2017","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"2021100415292870700_B19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ajcp\/107.3.379","article-title":"Graft-vs-host disease in the central nervous system","volume":"107","author":"Armstrong","year":"1997","journal-title":"Am J Clin Pathol."},{"issue":"4","key":"2021100415292870700_B20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ajcp\/89.4.543","article-title":"Graft-versus-host disease in the central nervous system. A real entity?","volume":"89","author":"Rouah","year":"1988","journal-title":"Am J Clin Pathol."},{"issue":"1","key":"2021100415292870700_B21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/19\/3789\/1824771\/advancesadv2021004889.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/19\/3789\/1824771\/advancesadv2021004889.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T04:00:35Z","timestamp":1633406435000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/19\/3789\/476813\/Fatal-late-onset-CAR-T-cell-mediated-encephalitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":21,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,10,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004889","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]}}}